Search
Brensocatib
go.drugbank.com/drugs/DB15638Approved[A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation.
Synonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamideCeruletide
go.drugbank.com/drugs/DB00403ApprovedCaerulein is a specific decapeptide similar in action and composition to the natural gastrointestinal peptide hormone cholecystokinin. … It exerts stimulatory effects on the gastric, biliary, and pancreatic secretion, as well as on certain smooth muscles.
Simoctocog alfa
go.drugbank.com/drugs/DB09108ApprovedIt is an antihemorrhagic agent used as a replacement therapy in individuals with Haemophilia A who lack the factor VIII in the intrinsic pathway of blood coagulation system. … Simoctocog alfa is a fourth-generation BDD FVIII product made in the human embryonic kidney (HEK) cell line.
Thiram
go.drugbank.com/drugs/DB13245ApprovedThiram may be used in dermatology as a scabicide [T436]. … Thiram is mainly used as a fungicide for plants and treatment for seeds, however, this use is being investigated for safety in many markets including Canada [L5425].
Categories: Compounds used in a research, industrial, or household settingOteracil
go.drugbank.com/drugs/DB03209ApprovedInvestigationalApproved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells.
Olopatadine
go.drugbank.com/drugs/DB00768Approved[A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations … An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively.
Sulfamethoxazole
go.drugbank.com/drugs/DB01015ApprovedInvestigationalin the biosynthesis of nucleic acids and proteins which are necessary for bacterial growth and division, and using them in conjunction helps to slow the development of bacterial resistance. … [L11830] It is generally given in combination with [trimethoprim], which inhibits a sequential step in bacterial folic acid synthesis - these agents work synergistically to block two consecutive steps
Synonyms: 4-Amino-N-(5-methyl-3-isoxazolyl)benzenesulfonamideMixtures: COTRIM E RATIO 480MG/5ML, EUSAPRIM E SUSPENS F ERWAminophenazone
go.drugbank.com/drugs/DB01424ApprovedWithdrawnIn biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests.
Pertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIt was first approved by the FDA in 2012 for use with [docetaxel] and another HER2-targeted monoclonal antibody, [trastuzumab], in the treatment of metastatic HER2-positive breast cancer. … Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
Metocurine iodide
go.drugbank.com/drugs/DB00416ApprovedWithdrawnIt is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine … Metocurine Iodide is no longer available on the US market.